Merck’s Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting
Merck & Co (NYSE:MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment…
Apple’s MagSafe Chargers Could Interfere With Cardiac Implants, Warns American Heart Association
Apple Inc’s (NASDAQ: AAPL) MagSafe devices could interfere with pacemakers if they are held very close to the implant or held over the skin, according to American Heart Association, Appleinsider
Medtronic Pulls Plug On Heart Implant Device Amid Growing Concerns Over Patient Safety
Medtronic PLC (NYSE: MDT) announced Thursday that it is stopping the distribution and sale of the Medtronic HVAD System, an implantable heart pump, after numerous data indicated higher occurrences of adverse events, including stroke and mortality, as compared to other circulatory-support devices.
Why Senseonics Shares Are Rocketing Higher After Hours Thursday
Study results from a glucose monitoring company were reported after market close Thursday.
Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial
Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001…
Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals
Bayer AG (OTC:BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the…
Novartis’ Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months
Novartis AG (NYSE:NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of…
Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters
Bristol Myers Squibb Co (NYSE:BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments…
Merck Completes Women’s Health Organon Spinoff
In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women’s health business into a standalone spinoff.
Oyster Point Introduces ETF Gene Therapy, First Candidate to Target Neurotrophic Keratopathy
Oyster Point Pharma Inc (NASDAQ:OYST) has announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene…